PSNL - Personalis provides preliminary Q4 numbers biopharma revenue expected to increase 73%

Personalis (PSNL) reports Q4 preliminary revenue of ~20.2M, vs $18.2M previously, representing an increase of 11%. For the FY 2020, revenue is estimated to be ~$78.6M compared with $65.2M for 2019, representing an increase of 21%.Preliminary revenue from biopharma and all other customers of an estimated ~$7.6M in Q4 compared with $4.4M Q4 2019, a 73% increase.Preliminary cash, cash equivalents, and short-term investments were estimated to be $203M as of December 31, 2020.“I’m proud to say that we were able to report record revenue once again this quarter and achieved our first $20M revenue quarter, despite the impact from the COVID-19 pandemic. Biopharma revenue was strong and customer orders were once again above revenue reported. In addition, we have several customers that have placed orders for our liquid biopsy offering, which we expect will be an important driver of growth in the future.” commented John West, CEO.Press Release

For further details see:

Personalis provides preliminary Q4 numbers, biopharma revenue expected to increase 73%